Abstract Submission is Extended to
20 January 2023 23:59 PST
Authors are invited to submit original unpublished papers for oral or poster presentations. Oral presentations will be allotted a 20-minute period, while poster presentations will be exhibited for at least a day.
All submissions should be in English and will undergo a peer-review evaluation on the originality of the work, scientific soundness, completeness, and accuracy, coherence of the content, and compliance with the format.
The Technical Papers Committee reserves the right to reassign papers if necessary. The submission for a paper presentation does not automatically indicate the registration of a participant. Registration to the conference is a separate process.
Deadline of submission of abstracts is on 22 December 2022. All abstracts will be reviewed by a panel of evaluators and the authors of accepted papers will be notified not later than 06 January 2023.
The poster should be printed in portrait [Size: A0 (841 x 1189 millimeters or 33.110 x 46.811 inches)]. It should include the header (title, author(s), affiliation(s) and contact details), abstract, introduction, methodology, results and discussion, conclusions, and references/acknowledgements. Chemical nomenclature should conform to IUPAC rules and measurements should be in SI units.
For the abstract, use a maximum of 250 words to convey the breakthrough and highlights of the study. For the figures and tables, number them sequentially and provide an appropriate caption, place it above for tables or below for figures. Include legends and other details as necessary. Cite major references using an appropriate citation style (i.e. APA) and acknowledge funding agencies and partner institutions as necessary.
Poster ingress is on Feb 14, 2023, from 1:00 – 5:00 at the Grand Ballroom (2nd floor of the BI Buenaventura Paredes OP (BGPOP) Alumni Center University of Santo Tomas, Espana, Manila. Posters should be posted prior to the first day of the conference.
Abstract Submission Guidelines
- Abstracts must be submitted on the understanding that they have not been presented elsewhere (except in the form of a thesis/dissertation) and are not being considered by another conference.
- All submitted abstracts will undergo a peer-review screening process and are expected to meet the standards of academic excellence.
- One presentation (oral or poster) per officially registered participant is allowed.
Mode of Submission
- All abstracts must be written in English.
- Authors must indicate which mode (oral or poster) is preferred. IC2 Paper Committee reserves the right to reassign modality, when necessary.
- Submission link: https://forms.gle/WvmHFDXsKx8c1gku5
- Upload the pdf file with a max size of 1MB only with the file name format: Surname. Type of Presentation (e.g. Santos_Oral).
The structured abstract should be written in English with no more than 250 words. It should include background and objectives, methods, results, conclusions, and a maximum of six (6) keywords. Chemical nomenclature should conform to IUPAC rules and measurements should be in SI units.
Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice
Background: Despite considerable progress in the development of anticancer therapies, there is still a high mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought to be a source of tumor relapse and metastasis, and are therefore an obstacle to therapy. In this study, we assessed the drug resistance of tumor cells in mice, and investigated whether vaccination could promote survival.
Methods: The mouse colon carcinoma cell line CT-26 was treated with 5-fluorouracil to assess its sensitivity to drug treatment. Mice with colon tumors were immunized with inactivated slow-cycling CT-26 cells to estimate the efficacy of this vaccine.
Results: We identified a small population of slow-cycling tumor cells in the mouse colon carcinoma CT-26 cell line, which was resistant to conventional chemotherapy. To inhibit tumor recurrence and metastasis more effectively, treatments that selectively target the slow-cycling tumor cells should be developed to complement conventional therapies. We found that drug-treated, slow-cycling tumor cells induced a more intense immune response in vitro. Moreover, vaccination with inactivated slow-cycling tumor cells caused a reduction in tumor volume and prolonged the overall survival of tumor-bearing mice.
Conclusions: These findings suggest that targeting of slow-cycling tumor cells application using immunotherapy is a possible treatment to complement traditional antitumor therapy.
Keywords: cancer relapse; drug resistance; slow-cycling tumor cells; tumor vaccine
Sun, Q., Zhong, Y., Wu, F. et al. Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice. BMC Med 10, 172 (2012). https://doi.org/10.1186/1741-7015-10-172